Full-Time

Director – Pipeline Strategy

Posted on 7/8/2024

Arcellx

Arcellx

51-200 employees

Develops immunotherapies for cell therapy

Compensation Overview

$230k - $255k/yr

+ Bonus + Equity Grant

Senior, Expert

San Carlos, CA, USA

Relocation assistance is offered if required.

Category
Biology Lab & Research
Biology & Biotech
Required Skills
Risk Management
Requirements
  • PhD or MD with 8+ years of industry experience.
  • Expertise in developing immunotherapies for cancer.
  • Broad understanding of the evolving clinical and global commercial landscape in oncology, autoimmune and inflammatory diseases, and cell therapy.
  • Outstanding strategic planning and analytical skills with the ability to synthesize findings and articulate implications from multiple sources of information to formulate strong recommendations and uncover market opportunities.
  • Mastery of project management tools and timeline management.
  • Demonstrated experience leading at scale, motivating teams, and influencing senior leaders and key stakeholders.
  • Ability to take initiative, build productive relationships, work cross-functionally, and manage multiple projects.
Responsibilities
  • Accountable for developing and driving project strategy with scientific rigor in alignment with portfolio strategy.
  • Manage the project timeline and budget across cross-functional workstreams, ensuring alignment of key deliverables, anticipating and mitigating risks, and driving accountability across the organization.
  • Partner with functional leads to support CMC development and commercialization activities and ensure adequate clinical supply for the early and late-stage portfolio.
  • Identify, develop, articulate, and present strategic options to make the best trade-off decisions within a project (e.g., technical product profile alterations, clinical product considerations) and across the portfolio as needed given changing market conditions or key early-stage data outputs.
  • Present critical program updates for data read-outs or notable preclinical / clinical milestones to senior leadership.
  • Ensure appropriate visibility to the organization on timeline, progress-to-date, upcoming key milestones, and identified risks.
  • Escalate and resolve key issues with the senior management team.

Arcellx develops immunotherapies aimed at improving cell therapy for serious diseases. Their products focus on harnessing the body's immune system to fight illnesses. The company works closely with healthcare providers and research institutions to create and test these therapies, which are designed to be safe and effective. Unlike many competitors, Arcellx emphasizes proprietary techniques in their research and development process, which allows them to create unique treatment options. The main goal of Arcellx is to meet unmet medical needs by providing advanced therapies that can significantly improve patient outcomes.

Company Size

51-200

Company Stage

IPO

Headquarters

Gaithersburg, Maryland

Founded

2014

Simplify Jobs

Simplify's Take

What believers are saying

  • Global CAR-T market projected to grow at 34.5% CAGR until 2030.
  • FDA's support for fast-tracking therapies benefits Arcellx's product approvals.
  • Partnerships with Kite enhance Arcellx's research and development capabilities.

What critics are saying

  • Intensifying competition from companies like Bristol-Myers Squibb and Johnson & Johnson.
  • High development costs may limit accessibility of Arcellx's therapies.
  • Reliance on partnerships exposes Arcellx to partner performance risks.

What makes Arcellx unique

  • Arcellx's CART-ddBCMA has FDA Fast Track and Orphan Drug designations.
  • ARC-SparX offers dosable and controllable CAR-T therapy options.
  • Anito-cel uses a novel D-Domain BCMA binder for enhanced cell killing.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Unlimited Paid Time Off

Flexible Work Hours

401(k) Company Match

Fully-Paid Parental Leave

Tuition Reimbursement

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

1%

2 year growth

4%
Business Wire
Mar 20th, 2025
Arcellx Appoints Andrew Galligan and Kristin Myers to Its Board of Directors

Arcellx appoints Andrew Galligan and Kristin Myers to its Board of Directors.

BioSpace
Feb 28th, 2025
Arcellx To Participate At The Td Cowen 45Th Annual Health Care Conference

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced that management will participate in a fireside chat at the TD Cowen 45th Annual Health Care Conference on Wednesday, March 5, at 1:10 p.m. ET.A live webcast of this discussion will be accessible from Arcellx’s website at www.arcellx.com in the Investors section. A replay of the webcast will be archived and available for 30 days following the event.About Arcellx, Inc.Arcellx, Inc. is a clinical-stage biotechnology company reimagining cell therapy by engineering innovative immunotherapies for patients with cancer and other incurable diseases. Arcellx believes that cell therapies are one of the forward pillars of medicine and Arcellx’s mission is to advance humanity by developing cell therapies that are safer, more effective, and more broadly accessible

Business Wire
May 9th, 2024
Kite And Arcellx Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX) today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Business Wire
May 9th, 2024
Arcellx And Kite Continue Momentum With Advances In Anito-Cel Multiple Myeloma Program

REDWOOD CITY, Calif. SANTA MONICA, Calif.--(BUSINESS WIRE)--Arcellx, Inc. (NASDAQ: ACLX) and Kite, a Gilead Company (NASDAQ: GILD), today announced several key operational updates on their partnered anitocabtagene autoleucel (anito-cel) multiple myeloma program. Anito-cel is the first BCMA CAR T to be investigated in multiple myeloma that utilizes Arcellx’s novel and compact D-Domain binder. The companies shared the design of a global, Phase 3 randomized controlled clinical trial, iMMagine-3, which Kite expects to start in the second half of this year. The trial will compare the efficacy and safety of anito-cel randomized against the standard of care (SOC) in patients with relapsed and/or refractory multiple myeloma (rrMM) who have received one to three prior lines of therapy, including an immunomodulatory drug (lMiD) and an anti-CD38 monoclonal antibody

Yahoo Finance
Mar 2nd, 2024
Earnings Update: Arcellx, Inc. (NASDAQ:ACLX) Just Reported And Analysts Are Boosting Their Estimates

Arcellx, Inc. (NASDAQ:ACLX) just released its full-year report and things are looking bullish.

INACTIVE